Sunday, 10 Aug 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    MiTAC Computing Partners with Industry Leaders on Open AI Server Solutions at OCP APAC Summit 2025
    MiTAC Computing Partners with Industry Leaders on Open AI Server Solutions at OCP APAC Summit 2025
    09/08/2025
    NOTICE OF SETTLEMENT APPROVAL
    NOTICE OF SETTLEMENT APPROVAL
    09/08/2025
    BBBS & Israel’s Foresight Awarded USD 5 Million to Build & Commercialize Rugged Autonomous Drones for Hazardous Industrial Environments
    BBBS & Israel’s Foresight Awarded USD 5 Million to Build & Commercialize Rugged Autonomous Drones for Hazardous Industrial Environments
    09/08/2025
    JioStar Presents Bigg Boss 19: A New Season, A New Sarkaar
    JioStar Presents Bigg Boss 19: A New Season, A New Sarkaar
    08/08/2025
    NOTICE OF SETTLEMENT APPROVAL
    Torus Digital enters strategic partnership with Suryoday Small Finance Bank, launches 3-in-1 Savings & Investment Account
    08/08/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • news
  • june
  • july
  • global
  • Business
  • today
  • announced
  • Tech
  • company
  • will
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Business

Circle Pharma Receives FDA Orphan Drug Designation for CID-078 for the Treatment of Small Cell Lung Cancer

Business Wire
Last updated: 16/06/2025 4:54 PM
Business Wire
Share
4 Min Read
Circle Pharma Receives FDA Orphan Drug Designation for CID-078 for the Treatment of Small Cell Lung Cancer
SHARE
Circle Pharma Receives FDA Orphan Drug Designation for CID-078 for the Treatment of Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–#Biotech–Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CID-078 for the treatment of small cell lung cancer (SCLC).

- Advertisement -


- Advertisement -

Small-cell lung cancer is a highly aggressive form of lung cancer that accounts for approximately 13–15% of all lung cancer cases1 and is strongly linked to tobacco exposure. Despite existing treatments, SCLC has a high recurrence rate and is associated with poor overall prognosis. While improvements in overall survival are occurring with newer therapies, most patients experience rapid disease progression2.

“The Orphan Drug Designation from the FDA underscores both the seriousness of small cell lung cancer and the lack of effective treatment options,” said Michael C. Cox, PharmD, MHSc, BCOP, SVP, and head of early development Circle Pharma. “We are committed to accelerating the clinical development of CID-078 to offer new hope for patients who face limited therapeutic choices.”

- Advertisement -

The FDA’s Orphan Drug Designation program is intended to promote the development of drugs for rare diseases or conditions affecting fewer than 200,000 people in the United States3. This designation provides several development incentives, including seven years of market exclusivity upon regulatory approval, tax credits for qualified clinical trial costs, and eligibility to apply for FDA-administered research grants4.

- Advertisement -

Circle Pharma has initiated a Phase 1 clinical trial (NCT06577987) of CID-078 to evaluate its safety, tolerability, pharmacokinetics, and early signs of anti-tumor activity in patients with advanced solid tumors, including SCLC.

About CID-078, Circle Pharma’s Cyclin A/B RxL Inhibitor Program


- Advertisement -

CID-078 is an orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation. In biochemical and cellular studies, Circle Pharma’s cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and Myt1 (a modulator of cyclin B). Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple in vivo models. A multi-center phase 1 clinical trial (NCT06577987) is currently enrolling patients.

- Advertisement -

About Circle Pharma, Inc.

South San Francisco-based Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop therapies for cancer and other serious illnesses. The company’s proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies for historically undruggable targets. Circle Pharma’s pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. Its lead program, CID-078, a cyclin A/B-RxL inhibitor, is in a Phase 1 clinical trial (NCT06577987) for patients with advanced solid tumors.

- Advertisement -

To learn more about Circle Pharma, please visit www.circlepharma.com.

- Advertisement -
  1. American Cancer Society. What is Small Cell Lung Cancer? https://www.cancer.org/cancer/lung-cancer/about/what-is.html
  2. National Cancer Institute. Small Cell Lung Cancer Treatment (PDQ®)–Patient Version. https://www.cancer.gov/types/lung/patient/small-cell-lung-treatment-pdq
  3. U.S. Food and Drug Administration. Developing Products for Rare Diseases & Conditions. https://www.fda.gov/industry/developing-products-rare-diseases-conditions
  4. U.S. Food and Drug Administration. Benefits of Orphan Drug Designation. https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products

 

Contacts

- Advertisement -

Media Contact:
Roslyn Patterson

Phone: 650.825.4099

Email: roslyn.patterson@circlepharma.com

- Advertisement -
D-Link Unveils Next-Generation Wi-Fi 7 Routers to Redefine Home and Small Business Networking
ZTE CDO Cui Li Highlights Efficient and Green AI as a Driver of SDGs Progress at AI for Good Global Summit
Cisco Unveils Secure Network Architecture to Accelerate Workplace AI Transformation
RLJ Lodging Trust Announces Dividends for Second Quarter of 2025
Hello Sunshine Launches Sunnie, New Multimedia and Experiential Brand for and by the Next Generation of Storytellers, Creators, and Changemakers
TAGGED:advancingannouncedbiopharmaceuticalcalifbusinesscancercancerscellcidclinicalstagecompanydesignationdevelopmentdifficulttotreatdrugfdafranciscolungmacrocycleorphanoverallpatientspharmasansclcsmallsouththerapeuticstodaytreatmentwirebiotechcircle
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

Draig Therapeutics Launches with 0 Million (107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders
Health

Draig Therapeutics Launches with $140 Million (107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders

18/06/2025
Centrum Broking Launches GalaxC – A Unified Investment and Trading Platform
Business

Centrum Broking Launches GalaxC – A Unified Investment and Trading Platform

10/07/2025
Star Health Insurance Partners with Medi Assist to Transform Claims through AI and Digital Innovation
Health

Star Health Insurance Partners with Medi Assist to Transform Claims through AI and Digital Innovation

07/07/2025
LINE Investors Have Opportunity to Lead Lineage, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Business

LINE Investors Have Opportunity to Lead Lineage, Inc. Securities Fraud Lawsuit with the Schall Law Firm

04/08/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?